Cyclacel Pharmaceuticals (NASDAQ:CYCC) just reported results for the second quarter of 2024.
- Cyclacel Pharmaceuticals reported earnings per share of -72 cents. This was above the analyst estimate for EPS of -$1.43.
- The company reported revenue of $4,000.
- This was 86.67% worse than the analyst estimate for revenue of $30,000.